Yazar "Yavuz, Fatma" seçeneğine göre listele

Listeleniyor 1 - 3 / 3
  • Küçük Resim Yok
    Öğe
    Atherogenic index of plasma: a useful marker for subclinical atherosclerosis in ankylosing spondylitis
    (Springer London Ltd, 2018) Cure, Erkan; Icli, Abdullah; Uslu, Ali Ugur; Sakiz, Davut; Cure, Medine Cumhur; Baykara, Rabia Aydogan; Yavuz, Fatma
    Ankylosing spondylitis (AS) is associated with an increased risk of atherosclerotic cardiovascular disease (ACD). The atherogenic index of plasma (AIP), which is the logarithmic transformation of the plasma triglyceride (TG) level to the high-density lipoprotein level (HDL) ratio, has been suggested to be a novel marker in the identification of atherosclerosis risk. Therefore, this study aims to determine if the AIP can act as an accurate marker for the detection of subclinical atherosclerosis. Fifty-two male patients with AS and 52 age-, gender-, and body mass index (BMI)-matched healthy control subjects were included in the study. For each patient, AIP and total cholesterol (TC)/HDL values were calculated and carotid artery intima-media thickness (cIMT) was measured. The mean (SD) cIMT and median (range) AIP values for AS patients were higher than that of the healthy control subjects (0.60 +/- 0.18 vs. 0.51 +/- 0.10, p = 0.003 and 0.23 [- 0.32 to 0.85] vs. 0.09 [- 0.53 to 0.49], p = 0.007, respectively). A positive correlation was found between the patients' cIMT and AIP values (r = 0.307, p = 0.002) and TC/HDL values (r = 0.241, p = 0.014). Regression analysis revealed an independent association between the subclinical atherosclerosis and AIP (beta [beta] = 0.309, p = 0.002). There were no independent correlations between subclinical atherosclerosis and TC (beta = 0.245, p = 0.065), TG (beta = 0.185, p = 0.515), HDL (beta = 0.198, p = 0.231), TC/HDL (beta = 0.032, p = 0.862), and low-density lipoprotein (LDL) (beta = 0.151, p = 0.246). A strong and independent correlation exists between AIP and cIMT values. Therefore, the AIP could serve as a better marker than the TC/HDL ratio for the detection of subclinical atherosclerosis in AS patients.
  • Küçük Resim
    Öğe
    Kronik hepatit B enfeksiyonu olan hastalarda serum iskemik modifiye albumin düzeyi ve fibrozisle ilişkisinin saptanması
    (Necmettin Erbakan Üniversitesi Meram Tıp Fakültesi, 2015) Yavuz, Fatma; Ataseven, Hüseyin
    Hepatit B virüs (HBV) enfeksiyonu ülkemizde sık görülen bir hastalıktır. HBV nedeniyle oluşan kronik viral hepatitlerin tanısında ve tedavi yanıtlarını değerlendirmek amacı ile kullanılan en iyi yöntem karaciğer biyopsisidir. Karaciğer hasarını saptamada kullanılabilecek noninvaziv test arayışına yönelik çalışmalar yapılmaktadır. İskemik Modifiye Albumin (IMA) kronik kronik karaciğer hastalıklarında, karaciğerdeki hasarla birlikte yükseldiği saptanan bir moleküldür. Çalışmadaki amacımız kronik hepatit B hastalarında karaciğer hücre hasarı ve derecesi ile ilgili bulguları noninvaziv bir yöntem olan IMA ile karaciğer biyopsisini karşılaştırılmış olarak incelemektir.Çalışmaya dahil edilen tüm KHB hastalarının ortalama IMA düzeyi 0.330 ± 0.116 ABSU, kontrol grubunun IMA düzeyi ise 0.271 ± 0.70 ABSU ölçülmüştür. İki grup arasında anlamlı fark saptanmıştır.Serum IMA ve IMAR düzeyleri KHB'li hastalarda karaciğer fibrozisin varlığını ve evresini göstermede birer serum belirleyicisi olarak değerlendirilebilir. Karaciğer biyopsisine alternatif olarak kullanılabilecek noninvaziv markır arayışına katkı sağladığını düşünüdüğümüz çalışmamız seri IMA ölçümleri yapılarak tekrarlanabilir.
  • Küçük Resim
    Öğe
    Serum ischemic modified albumin (IMA) concentration and IMA/albumin ratio in patients with hepatitis B-related chronic liver diseases
    (2017) Yavuz, Fatma; Bıyık, Murat; Asıl, Mehmet; Dertli, Ramazan; Demir, Ali; Polat, Hakkı; Uysal, Saliha; Ataseven, Hüseyin
    Background/aim: Albumin is the most important protein synthesized by the liver. Posttranscriptional changes occur in the molecular structure of albumin due to various factors and isoforms arise. Ischemic modified albumin (IMA) is one such isoform. This study was conducted to evaluate serum IMA concentrations in patients with hepatitis B virus (HBV)-related chronic liver diseases. Materials and methods: This study included 74 treatment-naive chronic hepatitis B patients, 25 patients with HBV-related cirrhosis, and 49 healthy controls. Serum IMA concentration was measured spectrophotometrically using the albumin cobalt binding test. Results: The mean IMA concentrations in the chronic hepatitis B group and healthy controls were 0.33 ± 0.11 ABSU and 0.27 ± 0.70 ABSU, respectively, and the difference was statistically significant. Mean IMA/albumin ratios (IMAR) in the chronic hepatitis B and control groups were 0.08 ± 0.04 and 0.06 ± 0.17, respectively, and the difference was also statistically significant (P > 0.001). Higher serum IMA concentrations and IMAR were detected in patients with advanced fibrosis. Conclusion: Serum IMA concentration and IMAR are increased in patients with HBV-related chronic liver diseases and IMA and IMAR are associated with the degree of liver fibrosis. IMA and IMAR may have potential use as noninvasive markers of fibrosis in chronic hepatitis B patients.